In a selected group of patients with CPA, weekly subcutaneous injections of interferon gamma (IFNγ) has been shown to improve disease control (reduced frequency of exacerbation and hospitalisation) and also helps with bacterial clearance [50]. The gene discussed is IFNG; the disease is congenital primary aphakia.